Brokerages Set Assembly Biosciences, Inc. (NASDAQ:ASMB) PT at $41.75

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $41.75.

Several analysts have recently commented on ASMB shares. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research report on Monday, December 22nd. Mizuho set a $40.00 price objective on Assembly Biosciences and gave the stock an “outperform” rating in a research report on Thursday, November 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st.

Assembly Biosciences Stock Up 4.2%

Assembly Biosciences stock opened at $29.95 on Friday. The firm has a market capitalization of $473.81 million, a PE ratio of -6.25 and a beta of 1.13. Assembly Biosciences has a 52 week low of $7.75 and a 52 week high of $39.71. The firm’s 50-day simple moving average is $29.77 and its 200 day simple moving average is $29.17.

Institutional Trading of Assembly Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Informed Momentum Co LLC raised its stake in Assembly Biosciences by 1.6% in the 4th quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock valued at $1,004,000 after purchasing an additional 451 shares during the last quarter. ADAR1 Capital Management LLC raised its position in shares of Assembly Biosciences by 4.2% in the fourth quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock valued at $672,000 after buying an additional 800 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Assembly Biosciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock valued at $4,468,000 after buying an additional 1,212 shares during the period. Palumbo Wealth Management LLC lifted its stake in shares of Assembly Biosciences by 7.2% during the fourth quarter. Palumbo Wealth Management LLC now owns 37,305 shares of the biopharmaceutical company’s stock valued at $1,269,000 after buying an additional 2,507 shares during the period. Finally, Bank of America Corp DE boosted its position in Assembly Biosciences by 6,382.7% during the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 3,319 shares during the last quarter. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.